$27.8M Xarelto Verdict
December 7, 2017
On December 5, 2017, a Philadelphia pharmaceutical liability jury returned its verdict in the amount of $27.8 million in favor of a husband and wife regarding the wife’s internal bleeding allegedly caused by her use of the prescription blood-thinning medication Xarelto (rivaroxaban). The jury [...]
Continue Reading
First Xarelto Trial Results In Win For The Defendants
May 25, 2017
On May 3, 2017, a federal jury in Louisiana found against a Xarelto plaintiff who claimed that the defendants, Johnson & Johnson (“J & J”) and Bayer AG, had inadequately warned him regarding the internal bleeding risk associated with Xarelto, a blood-thinning medication that has [...]
Continue Reading
Xarelto Lawsuits Allege Undisclosed Risk of Internal Bleeding
April 27, 2017
More than 18,000 patients have filed lawsuits alleging that the blood-thinning medication Xarelto caused them to suffer internal bleeding, the risk of which they allege was not disclosed to them. Johnson & Johnson and Bayer jointly developed Xarelto, which was approved by the FDA in 2011 to be u[...]
Continue Reading
